Search by Drug Name or NDC

    NDC 55513-0326-01 Riabni 500 mg/50mL Details

    Riabni 500 mg/50mL

    Riabni is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Amgen Inc. The primary component is RITUXIMAB.

    Product Information

    NDC 55513-0326
    Product ID 55513-326_4d103e96-5706-47e3-bdb5-757964f9e379
    Associated GPIs 21351860142040
    GCN Sequence Number 081778
    GCN Sequence Number Description rituximab-arrx VIAL 10 MG/ML INTRAVEN
    HIC3 Z2W
    HIC3 Description ANTI-CD20 (B LYMPHOCYTE) MONOCLONAL ANTIBODY
    GCN 48996
    HICL Sequence Number 047033
    HICL Sequence Number Description RITUXIMAB-ARRX
    Brand/Generic Brand
    Proprietary Name Riabni
    Proprietary Name Suffix n/a
    Non-Proprietary Name rituximab-arrx
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route INTRAVENOUS
    Active Ingredient Strength 500
    Active Ingredient Units mg/50mL
    Substance Name RITUXIMAB
    Labeler Name Amgen Inc
    Pharmaceutical Class CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761140
    Listing Certified Through 2024-12-31

    Package

    NDC 55513-0326-01 (55513032601)

    NDC Package Code 55513-326-01
    Billing NDC 55513032601
    Package 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-326-01) / 50 mL in 1 VIAL, SINGLE-DOSE
    Marketing Start Date 2021-01-06
    NDC Exclude Flag N
    Pricing Information N/A